✦ LIBER ✦

A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

✍ Scribed by Deepak L. Bhatt; Keith A. Fox; Werner Hacke; Peter B. Berger; Henry R. Black; William E. Boden; Patrice Cacoub; Eric A. Cohen; Mark A. Creager; J. Donald Easton; Marcus D. Flather; Steven M. Haffner; Christian W. Hamm; Graeme J. Hankey; S. Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A. Pearson; P. Gabriel Steg; Steven R. Steinhubl; Michael A. Weber; Joan Booth; Eric J. Topol

Book ID: 116190163
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 114 KB
Volume: 150
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2005.03.017

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bleeding, mortality, and antiplatelet th

Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

✍ Jeffrey S. Berger; Deepak L. Bhatt; P. Gabriel Steg; Steven R. Steinhubl; Gilles 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 327 KB

Bleeding, mortality, and antiplatelet th

Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

✍ Saurav Chatterjee; Subhankar Maitra; Anasua Chakraborty 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Clopidogrel added to aspirin versus aspi

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

✍ Deepak L. Bhatt; Eric J. Topol 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Ethnic variation in adverse cardiovascul

Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study

✍ Koon-Hou Mak; Deepak L. Bhatt; Mingyuan Shao; Graeme J. Hankey; J. Donald Easton 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 421 KB

Reply to the letter by Chatterjee et al

Reply to the letter by Chatterjee et al “Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial”

✍ Jeffery S. Berger; Deepak L. Bhatt 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Clinical Outcomes of Patients With Diabe

Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)

✍ Arijit Dasgupta; Steven R. Steinhubl; Deepak L. Bhatt; Peter B. Berger; Mingyuan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 369 KB